Gasporox Q3 2023: Below expectations but still positive EBITDA - Redeye

Redeye comments on Gasporox Q3 2023 report which came in below estimates. with net sales growing 4% y/y and missing our estimates by 23%. EBITDA was positive for the fifth straight quarter (not adjusting for capitalized R&D), showing a 7% ETBIDA margin. We expect volatility in Gasporox's results and we expect to make only minior changes due to the report.

Länk till analysen i sin helhet: https://www.redeye.se/research/955845/gasporox-q3-2023-below-expectations-but-still-positive-ebitda?utm_source=finwire&utm_medium=RSS